Eisai enters joint research pact with four research organizations in Japan for development of...
Eisai Co Ltd announced that it has entered into a joint research agreement with four...
Syngene joins global industry consortium to accelerate collaborative research in COVID-19 testing
Syngene International Limited announced that it has joined a global consortium of 19 organizations from...
Regenerons REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-Hospitalized COVID-19 Patients
Regeneron Pharmaceuticals, Inc. announced the first data from a descriptive analysis of a seamless Phase...
Major Pharma Companies, Including Novartis And Merck, Build Federated Learning Platform For Drug Discovery
Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, GSK, Institut De Recherches Servier, Janssen, Merck, and Novartis...
Alnylam Pharmaceuticals partners with Sharp on packaging RNA interference (RNAi) therapeutics for Europe
Alnylam Pharmaceuticals Inc., the leading RNA interference (RNAi) therapeutics company, and Sharp, part of UDG...
Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations
Seattle Genetics, Inc. and Merck, known as MSD outside the United States and Canada, announced...
Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary...
Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a...
PharmAbcine signs a CMO contract with Binex so Binex can produce olinvacimab at its...
PharmAbcine, a biotech company focusing on the development of antibody therapeutics, announced on August 31...
Catalent and Exelixis Enter into Collaboration, License, and Exclusive Option Agreement to Develop ADC...
Exelixis, Inc. and Catalent announced a partnership under which Catalent’s Redwood Bioscience subsidiary will develop...
Enesi Pharma partners with Adelaide University for Zika vaccine
Enesi Pharma, an innovative biotechnology company developing next-generation vaccination products targeting serious diseases, is delighted...
